Nasdaq

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
Business Wire

Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly ...
Seeking Alpha

Immuneering: Clinical Catalyst In January, Cash Raised For Phase 3

Immuneering is developing atebimetinib, a novel MEK inhibitor, in multiple solid tumors, having already produced impressive phase 2a data in pancreatic cancer. IMRX's near-term catalyst is the January ...
Seeking Alpha

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism ...
Nasdaq

Reviva Pharmaceuticals Reports Completion of Brilaroxazine Long-Term OLE Trial and Upcoming Phase 3 RECOVER-2 Trial Initiation

Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...